Target Selection through Application of Chemical and Systems Biology and Attrition
01 April 2012 - 04 April 2012
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants will be limited to 35, to favour in depth discussion.
Castle "Oud Poelgeest", Oegstgeest, near Leiden, The Netherlands
http://www.ldorganisation.com/produits.php?langue=english&cle_menus=1238915523&cle_data=1238740799
2nd Annual Vaccines Congress
02 April 2012 - 03 April 2012
Over the two days, key opinion leaders will explore pioneering solutions and critical opportunities in preclinical development, clinical design and process enhancement. Delegates will hear from those working at the forefront of vaccine innovation in areas such as oncology and universal vaccines, while internationally recognised experts present sustainable strategies for long-term success in vaccines development, delivery, manufacturing and partnering.
Radisson Blu Portman Hotel, London, UK
http://www.vaccines-congress.com/
5th Annual Proteins Congress
02 April 2012 - 03 April 2012
The 5th Annual Proteins Congress is an exclusive event consisting of world-class keynote addresses and panel discussions designed specifically for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, academics, government, CRO and solution provider companies.
The Radisson Blu Portman Hotel, London, UK
http://www.proteins-congress.com/
Biologics World Korea
16 April 2012 - 19 April 2012
Biologics World Korea provides the ONLY biologics and biosimilars focused platform in Korea that brings together Korean and international biopharma leaders, innovative biotechs, and technocrats to convene and discuss on strategies, latest technologies and best practices.
Seoul, Korea
http://www.imapac.com/index.php?page=BiologicsWorldKorea2012
8th Stem Cell Summit
19 April 2012 - 20 April 2012
Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming, and regulatory policies regarding stem cell research will be addressed. In addition, focuses on the business opportunities, challenges and potential strategies for overcoming these challenges will be addressed. What categories of companies are currently commercially viable? How are they being funded? What kind of strategic relationships are available within the industry?
Hyatt Harborside, Boston, MA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=8th%20Stem%20Cell%20Summit&cid=22